Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) has announced an upcoming R&D Investor Event scheduled for Wednesday, April 23, 2025, at 8:30am EDT / 13:30pm BST in New York City. The event will feature key updates on:

• Clinical pipeline programs and expansion plans for obe-cel
• Initial data from six patients in the CARLYSLE Phase 1 trial for systemic lupus erythematosus (SLE)
• Development plans for expansion in autoimmune diseases
• Progress update on the commercial launch of AUCATZYL®

The presentation will be accessible via webcast on the company's website, with a 90-day replay period available. Interested parties can inquire about in-person attendance through the provided contact.

LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT / 13:30pm BST.

Autolus will present an update on clinical pipeline programs, including plans to expand the obe-cel opportunity. The Company expects to report initial data in six patients from the ongoing CARLYSLE Phase 1 trial in systemic lupus erythematosus (SLE), announce development plans for expansion in autoimmune diseases, and provide a brief update of the ongoing commercial launch of AUCATZYL^®.

A webcast of the presentation will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

The live event will be held in New York City. To inquire about in-person attendance please email: susan@sanoonan.com.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com

Contact:

Amanda Cray 
+1 617-967-0207 
a.cray@autolus.com 

Olivia Manser 
+44 7780 471 568 
o.manser@autolus.com 

FAQ

What will Autolus Therapeutics (AUTL) present at their April 2025 R&D Investor Event?

Autolus will present clinical pipeline updates, obe-cel expansion plans, CARLYSLE Phase 1 trial data for SLE patients, autoimmune disease development plans, and AUCATZYL® launch updates.

When and where is the Autolus Therapeutics (AUTL) R&D Investor Event taking place?

The event will be held in New York City on Wednesday, April 23, 2025, at 8:30am EDT / 13:30pm BST.

How can investors access Autolus Therapeutics' (AUTL) April 2025 R&D presentation?

Investors can watch via webcast on Autolus' website or attend in-person by emailing susan@sanoonan.com for attendance inquiries.

What clinical trial data will AUTL present at the April 2025 R&D Event?

AUTL will present initial data from six patients in the CARLYSLE Phase 1 trial for systemic lupus erythematosus (SLE).

How long will the AUTL R&D Event presentation replay be available?

The webcast replay will be archived on Autolus' website for 90 days following the presentation.